WASHINGTON (Reuters) – A U.S. court said on Friday that Martin Shkreli, who famously raised the price of Daraprim, would be ordered to pay $64.6 million and would be barred for life from the pharmaceutical industry.
The drug is used to treat toxoplasmosis, a parasitic infection that threatens people with weakened immune systems.
(Reporting by Diane Bartz)
